KMPH KemPharm Inc.

0.37
-0.04  -9%
Previous Close 0.41
Open 0.42
Price To Book -0.18
Market Cap 12,429,052
Shares 33,223,877
Volume 334,441
Short Ratio
Av. Daily Volume 177,015
Stock charts supplied by TradingView

NewsSee all news

  1. KemPharm Reports Third Quarter 2019 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 14, 2019, at 5:30 p.m. ET CELEBRATION, Fla., Nov. 14, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty

  2. KemPharm to Report Third Quarter 2019 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled forThursday, November 14, 2019, 5:30 p.m. ET CELEBRATION, Fla., Nov. 12, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty

  3. KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019

    KVK-Tech is Initially Stocking Selected Regions Based on Formulary Access CELEBRATION, Fla., Oct. 31, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery

  4. KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting

    Data Demonstrate that KP415 Can Be Administered without Regard to Food; Can Be Mixed into Foods or Drink CELEBRATION, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical

  5. KemPharm Provides Updates Regarding its Board of Directors

    CELEBRATION, Fla., Sept. 20, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that, on

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA filing due by January 2020.
KP415
ADHD
CRL issued June 13, 2016. Resubmitted, and issued FDA Approval February 23, 2018.
Apadaz (KP201/APAP)
Acute pain
Pivotal data due in 2020.
KP484
ADHD

Latest News

  1. KemPharm Reports Third Quarter 2019 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 14, 2019, at 5:30 p.m. ET CELEBRATION, Fla., Nov. 14, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty

  2. KemPharm to Report Third Quarter 2019 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled forThursday, November 14, 2019, 5:30 p.m. ET CELEBRATION, Fla., Nov. 12, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty

  3. KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019

    KVK-Tech is Initially Stocking Selected Regions Based on Formulary Access CELEBRATION, Fla., Oct. 31, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery

  4. KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting

    Data Demonstrate that KP415 Can Be Administered without Regard to Food; Can Be Mixed into Foods or Drink CELEBRATION, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical

  5. KemPharm Provides Updates Regarding its Board of Directors

    CELEBRATION, Fla., Sept. 20, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that, on

  6. KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases

    CELEBRATION, Fla., Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its

  7. KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.

    CELEBRATION, Fla., Sept. 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its

  8. KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital

    Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales KemPharm Will Host a Conference Call and Live Audio Webcast with Slide Presentation Today, Wednesday,